Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2


Brief Information

Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:24
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-L02H14-Cell-based assay

GMP Human IL-2 Protein (Cat. No. GMP-L02H14) stimulates proliferation of CTLL-2 cells. The specific activity of GMP Human IL-2 is ≥1.2*10^7 IU/mg, which is calibrated against human Interleukin-2 China National Standard (NIFDC code: 270008) (QC tested). China National Institutes for Food and Drug Control (NIFDC) Standard was prepared and calibrated against human IL-2 WHO International Standard (NIBSC code: 86/500) by NIFDC.

IL2-H5215-Cell-based assay

Human IL-2, premium grade (Cat. No. IL2-H5215) stimulates proliferation of CTLL-2 cells. The EC50 for this effect is 1.996 ng/mL, corresponding to a specific activity of  5 ⅹ10^6 IU/mg, which is calibrated against Interleukin-2 (Human, rDNA derived) (2nd International Standard) (NIBSC code: 86/500) (QC tested).


Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Mouse IL-2, His Tag (Cat. No. IL2-M52H3) immobilized on CM5 Chip can bind Mouse IL-2 R beta, Fc Tag (Cat. No. ILB-M5253) with an affinity constant of 36.2 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name

IL2,TCGF,lymphokine,Interleukin 2


Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SHR-1916 SHR-1916 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
SAR-444336 SAR-444336 Phase 1 Clinical Sanofi Inflammation Details
PM-1016 PM1016; TILT-123 Phase 2 Clinical Tilt Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Spa Solid tumours; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
attIL2-T cell therapy Phase 1 Clinical MD Anderson Cancer Center Soft Tissue Neoplasms; Osteosarcoma; Sarcoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
TransCon IL-2 β/γ Phase 2 Clinical Ascendis Pharma A/S Solid tumours; Ovarian Neoplasms; Neoplasm Metastasis Details
XTX-202 XTX-202 Phase 2 Clinical Xilio Development Inc Solid tumours Details
S-95007 S-95007 Phase 2 Clinical Laboratoires Servier Immune System Diseases; Inflammation Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Spa Carcinoma, Merkel Cell; Carcinoma, Skin Appendage; Basal Cell Nevus Syndrome; Keratoacanthoma; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi Details
ITI-1000 ITI-1000 Phase 2 Clinical Immunomic Therapeutics Inc Glioblastoma Details
Saltikva Phase 2 Clinical Salspera LLC Pancreatic Neoplasms Details
AU-007 BD-8; AU-007; BDG-8 Phase 2 Clinical Biolojic Design Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
NNC-0361-0041 NNC0361-0041; NNC-0361-0041 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1 Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Shanghai Keyi Pharmaceutical Technology Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MK-1484 MK-1484 Phase 1 Clinical Merck & Co Inc Solid tumours Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
AVB-001 AVB-001 Phase 2 Clinical Avenge Bio Inc Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
AB-248 AB-248 Phase 1 Clinical Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung Details
EQ101 EQ101 Phase 2 Clinical Equillium Inc Alopecia; Alopecia Areata Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message